---
title: "COL6A3"
date: 2023-05-12 00:00:00
layout: post
categories: Gene
summary: "# Gene Information Analysis: COL6A3"
tags: ['COL6A3', 'BethlemMyopathy', 'UllrichCongenitalMuscularDystrophy', 'ExtracellularMatrix', 'MissenseMutation', 'TreatmentOptions', 'Prognosis', 'DrugResponse']
---

# Gene Information Analysis: COL6A3

## Gene Position, Pathology, and Function

### Gene Position

The gene of interest is COL6A3, which is located on chromosome 2q37.3. 

### Pathology

COL6A3 is associated with several pathologies, including Bethlem myopathy and Ullrich congenital muscular dystrophy. 

### Function

COL6A3 encodes one of the three alpha chains of type VI collagen, which is a major extracellular matrix component in many tissues such as skin, bone, cartilage, and tendons. Type VI collagen is involved in the maintenance of structural integrity and function of these tissues. 

## External IDs and Aliases

| External ID | Genomic Location | Alias |
| --- | --- | --- |
| HGNC | HGNC:2215 | - |
| NCBI Entrez | 1292 | COL6A3 |
| Ensembl | ENSG00000171856 | - |
| OMIM | 120250 | Bethlem myopathy |
| UniProtKB/Swiss-Prot | Q2UY05 | - |

## AA Mutation List and Mutation Type with dbSNP ID

- p.Arg435Gly - missense - rs200745159
- p.Arg1200His - missense - rs267606932
- p.Lys1575Gln - missense - rs76747125
- p.Pro1906Arg - missense - rs267606933
- p.Ala2163Val - missense - rs782617199

## Somatic SNVs/InDels with dbSNP ID

- c.172G>A - synonymous - rs146047150
- c.431A>G - synonymous - rs774418184
- c.7T>A - synonymous - rs752225746

## Related Disease

COL6A3 mutations are associated with various disease conditions. Some of the diseases are listed below:
- Bethlem myopathy
- Ullrich congenital muscular dystrophy
- Familial hypertrophic cardiomyopathy

## Treatment and Prognosis

Currently, there is no cure for the diseases associated with COL6A3 mutations. Treatment is mainly aimed at managing symptoms and improving the quality of life of affected individuals. Physical therapy, orthopedic devices, and surgical procedures are commonly used to treat these diseases. Prognosis varies depending on the severity of the condition and the age of onset. 

## Drug Response

Currently, no drugs are specifically approved for the treatment of Bethlem myopathy or Ullrich congenital muscular dystrophy. However, some drugs, such as steroids and immunosuppressants, have been used experimentally in an attempt to improve muscle strength and function in affected individuals. 

## Related Papers

- Subject: Molecular basis of Ullrich congenital muscular dystrophy and Bethlem myopathy
  - Author: Jane V. Leonard and Francesco Muntoni
  - DOI: 10.1016/j.nmd.2004.07.005
- Subject: COL6-Related Disorders
  - Author: Saverio V. Giudice et al.
  - DOI: 10.1007/s11940-019-0576-z

**_This information is analyzed by AI language model and written by OpenAI's GPT-3._**